Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Atorvastatin in Moderate-to-severe Thyroid Eye Disease
NCT07762105Phase 1Not yet recruiting
- Sponsor
- Banu Aji Dibyasakti
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of atorvastatin in Graves Orbitopathy (GO) (2 arms), sponsored by Banu Aji Dibyasakti. Primary endpoint: Individual rectus muscle diameters at 24 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
atorvastatin
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on NCT07762105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762105.